Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVL-102
- Development stage
- Phase 1
- Lead developer
- Advaccine Biotechnology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
AVL-102 is an mRNA-based therapeutic human papillomavirus (HPV) vaccine developed by Beijing Advaccine Biotechnology (Advaccine) and its parent company Beijing Xunsheng Biomedical Research. It is designed to target four high-risk HPV subtypes: HPV16, HPV18, HPV52, and HPV58. Unlike prophylactic HPV vaccines that induce neutralizing antibodies to prevent infection, AVL-102 is a therapeutic vaccine that aims to stimulate a robust, antigen-specific T-cell immune response (specifically CD8+ cytotoxic T lymphocytes and CD4+ helper T cells) to recognize and eliminate HPV-infected cells and precancerous lesions. It is being evaluated in Phase I clinical trials in China for the treatment of untreated HPV-related high-grade intraepithelial lesions, including cervical, vulvar, vaginal, and anal lesions.
- Other names
- AVL-102注射液
Beyond the preview
Go deeper on AVL-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVL-102.